CANCER ANTIGEN -125 IN THE DETERMINATION OF SEVERITY IN CASES OF SEVERE PRE-ECLAMPSIA. | ||||
| ALEXMED ePosters | ||||
| Article 1, Volume 7, Issue 1, January 2025, Page 39-40 | ||||
| Document Type: Preliminary preprint short reports of original research | ||||
| DOI: 10.21608/alexpo.2025.360099.2093 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mohamed El-Samrah; Manal Shafik Swelem; Kaltume Mohammed 
| ||||
| Department; Obstetrics and Gyanacology Alexandra University Egypt. | ||||
| Abstract | ||||
| Pre-eclampsia is defined as hypertension that appears after 20 weeks of gestation, in addition to proteinuria or other indicators of injury to end organ damage during pregnancy , is a significant contributor to maternal and perinatal death and morbidity especially when it manifests early. Epidemeology. A pregnancy specific illness ,pre-eclampsia affects 3-5 % of expectant mothers ,high blood pressure, proteinuria and edema are one of its characteristics. Categorization of hypertensive disorders associated with pregnancy . 1. Pre-eclampsia. 2. Gestational hypertension. 3. Super imposed pre-eclampsia. 4. Chronic hypertension. Potential causes of pre-eclampsia. 1. Advanced maternal age. 2.Obesity. 3. Nulliparity. 4. Multi fetal pregnancy. 5. Family history of pre-eclampsia. 6. Previous history of pre-eclampsia COMPLICATIONS OF PRE-ECLAMPSIA. Maternal complications. 1. Eclampsia. 2. HELLP SYNDROME. 3. Cardiovascular complications. 4. Renal complications. 5. Neurological complications. Fetal complications. 1. fetal growth restriction. 2. Premarturity. AIM OF THE WORK. The aim of these study is to analyze the association of CA-125 values as an affordable and widely available , and establish its potential role in evaluation of pre-eclampsia severity. | ||||
| Keywords | ||||
| CANCER ANTIGEN; PRE-ECLAMPSIA; SEVERE | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 40 |
||||
